Sacha Salzberg. We anticipate further use and evaluation of this system. Drachman, President and CEO. This key invention represents a big and exciting new development platform and we anticipate full commercial launch in Europe and america during 2010. Michael J. Dr. Mack, the main investigator of the FDA multi-center trial for the AtriClip System, EXCLUDE, will be became a member of by Dr. Salzberg, the principal investigator of the European trial for the AtriClip Program, to go over their respective scientific trial results using this novel program.. CE Mark acceptance for AtriClip System AtriCure, Inc. , a medical device organization and a head in cardiac medical ablation systems, announced CE Mark approval for its AtriClip Gillinov-Cosgrove Still left Atrial Appendage Exclusion Program today.The strategy was inexpensive, basic and a much-needed advance in generating stem cells, Kiessling described. Related StoriesKey protein settings stem cell properties that will make them useful in regenerative medicinePublic policy needed to decrease stem cell tourism, say expertsFranziska Michor named recipient of NYSCF – Robertson Stem Cell PrizeWith the ability to grow stem cells on the synthetic areas under chemically defined, or known, conditions, Kiessling’s group took yet another part of their latest research. It discovered that defined surfaces may exert control more than signaling pathways chemically. ‘Signaling’ can be how molecules talk to each other and get points done in the cell. It’s how an immune cell understands to fight contamination or how a pancreatic cell determines that more insulin is necessary in the bloodstream, for instance.